NO20030139L - Farmasöytiske preparater inneholdende DDS forbindelser - Google Patents

Farmasöytiske preparater inneholdende DDS forbindelser

Info

Publication number
NO20030139L
NO20030139L NO20030139A NO20030139A NO20030139L NO 20030139 L NO20030139 L NO 20030139L NO 20030139 A NO20030139 A NO 20030139A NO 20030139 A NO20030139 A NO 20030139A NO 20030139 L NO20030139 L NO 20030139L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
preparations containing
dds compounds
containing dds
compounds
Prior art date
Application number
NO20030139A
Other languages
English (en)
Other versions
NO20030139D0 (no
Inventor
Masayuki Takahashi
Shuichi Sugie
Masahito Takeuchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO20030139D0 publication Critical patent/NO20030139D0/no
Publication of NO20030139L publication Critical patent/NO20030139L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030139A 2000-07-13 2003-01-10 Farmasöytiske preparater inneholdende DDS forbindelser NO20030139L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13
PCT/JP2001/006020 WO2002005855A1 (fr) 2000-07-13 2001-07-11 Compositions pharmaceutiques contenant des composes dds

Publications (2)

Publication Number Publication Date
NO20030139D0 NO20030139D0 (no) 2003-01-10
NO20030139L true NO20030139L (no) 2003-03-13

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030139A NO20030139L (no) 2000-07-13 2003-01-10 Farmasöytiske preparater inneholdende DDS forbindelser

Country Status (12)

Country Link
US (1) US6815435B2 (no)
EP (1) EP1308171A1 (no)
KR (1) KR20030023697A (no)
CN (1) CN1556712A (no)
AR (1) AR031714A1 (no)
AU (1) AU2001271037A1 (no)
BR (1) BR0112417A (no)
CA (1) CA2415922A1 (no)
MX (1) MXPA03000387A (no)
NO (1) NO20030139L (no)
RU (1) RU2003100532A (no)
WO (1) WO2002005855A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166513A1 (en) * 2000-06-29 2003-09-04 Akihiro Imura Dds compound and process for the preparation thereof
TWI320713B (no) 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
US20060147401A1 (en) * 2002-12-10 2006-07-06 Masaya Tanaka Skin material for external use and antiprutiric agent for external use and wrinkle-instrument using the same
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
NZ706991A (en) * 2010-03-29 2016-08-26 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
RU2633640C2 (ru) * 2011-09-16 2017-10-16 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
RU2717690C2 (ru) 2014-12-26 2020-03-25 Ниппон Каяку Кабусики Каися Фармацевтический состав полимерного производного, содержащего камптотецин
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
KR20180039628A (ko) 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
CA2231682A1 (en) 1995-09-13 1997-03-20 Junzo Seki Pge1-containing freeze-dried preparation and the production thereof
NZ331372A (en) 1996-02-19 2000-01-28 Nycomed Imaging As freeze-dried vesicle containing a thermally stabilized ultrasound contrast agent
WO1997035135A1 (en) * 1996-03-19 1997-09-25 The Morgan Crucible Company Plc. A conduit
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
EP1120116A1 (en) 1998-09-29 2001-08-01 Takeda Chemical Industries, Ltd. Antimycotic drug composition

Also Published As

Publication number Publication date
AU2001271037A1 (en) 2002-01-30
BR0112417A (pt) 2003-07-01
CA2415922A1 (en) 2002-01-24
AR031714A1 (es) 2003-10-01
WO2002005855A1 (fr) 2002-01-24
EP1308171A1 (en) 2003-05-07
MXPA03000387A (es) 2003-09-22
US20030148931A1 (en) 2003-08-07
US6815435B2 (en) 2004-11-09
KR20030023697A (ko) 2003-03-19
NO20030139D0 (no) 2003-01-10
CN1556712A (zh) 2004-12-22
RU2003100532A (ru) 2004-07-20

Similar Documents

Publication Publication Date Title
NO20030139D0 (no) Farmasöytiske preparater inneholdende DDS forbindelser
NO20071303L (no) Farmasoytiske preparater
NO20033556D0 (no) Farmasöytiske preparater
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
ITTO20010008A0 (it) Formulazione farmaceutica
NO20020304L (no) Konserverte farmasoytiske preparater
NO20020464L (no) Flerkomponents farmasöytisk doseringsform
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
ATE238812T1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
NO20030627L (no) Hydrogel-drevet medikament doseringsform
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
MXPA03001425A (es) Compuestos farmaceuticos.
NO20026013D0 (no) Medisinske preparater inneholdende propenonderivater
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
NO20014926L (no) Farmasöytiske forbindelser
EE200300135A (et) Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid
DE69926012D1 (de) Arzneizubereitungen
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430D0 (no) Farmasöytisk kompleks
DE69906934D1 (de) Arzneizubereitungen
EP1142589A4 (en) Medicinal preparations
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application